Jiangsu vcare pharmaceutical technology co., LTD

Quick facts

Phase 3 pipeline

• VC004 Capsules · Diabetes
  VC004 Capsules is a small molecule drug that targets the SGLT2 receptor.
• VC005 · Diabetes
  VC005 is a small molecule that targets the SGLT2 receptor.
• VC005 high dose group · Diabetes
  VC005 is a small molecule that targets the SGLT2 receptor.
• VC005 low dose group · Diabetes
  VC005 is a small molecule that targets the SGLT2 receptor.
• VC005 Tablets · Diabetes
  VC005 Tablets is a small molecule drug that targets the SGLT2 receptor.
• Vicagrel · Other

Phase 2 pipeline

• Tofacitinib Citrate Tablets
• VC005 groups

Phase 1 pipeline

• [14C]VC005
• [14C]Vicagrel
• Median Dose VC004 Capsules
• VC004
• VC004 and Itraconazole
• VC004 and rifampicin
• VC005 Tablets food effects group
• Vicagrel and omeprazole
• Vicagrel Capsules

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Jiangsu vcare pharmaceutical technology co., LTD portfolio CI brief
• Jiangsu vcare pharmaceutical technology co., LTD pipeline updates RSS